KR-102961086-B1 - Use of a type of Chinese medicine composition in the manufacture of drugs for the treatment of neurogenic pulmonary edema

Abstract

In a Chinese medicine composition for treating a type of neurogenic pulmonary edema, the Chinese medicine composition is prepared by including Angelica dahurica, Aralia continentalis, Poria cocos, Saposhnikovia divaricata, Schizonepeta tenuifolia, Ligusticum chuanxiong, Platycodon grandiflorus, Bupleurum chinense, Peucedanum praeruptorum, Citrus aurantium, and Glycyrrhiza glabra. The Chinese medicine composition can improve lung fluid and lung dampness/dryness in rats with neurogenic pulmonary edema, thus having a therapeutic effect on neurogenic pulmonary edema.

Inventors

• 장 구이민
• 야오 징춘
• 선 쳉홍
• 리 홍화

Assignees

• 산동 뉴 타임 파마슈티칼 코., 리미티드.

Dates

Publication Date

20260507

Application Date

20220929

Priority Date

20210930

Claims (9)

1. A Chinese medicinal composition for the prevention or treatment of neurogenic pulmonary edema, comprising *Schizonepeta tenuifolia*, *Saposhnikovia divaricata*, *Angelica dahurica*, *Aralia continentalis*, *Bupleurum chinense*, *Peony pea*, *Cnidium officinale*, *Prunus persica*, *Poria cocos*, *Platycodon grandiflorus*, and *Glycyrrhiza glabra*, wherein the Chinese medicinal composition is prepared from the following raw materials in parts by weight: 5-30 parts by weight of *Hyeonggae*, 5-30 parts by weight of *Bangpung*, 5-30 parts by weight of *Ganghwal*, 5-30 parts by weight of Aralia continentalis, 3-25 parts by weight of Bupleurum chinense, 3-25 parts by weight of Angelica dahurica, 5-30 parts by weight of Cnidium officinale, 3-25 parts by weight of Citrus aurantium, 5-30 parts by weight of Poria cocos, 3-25 parts by weight of balloon flower root, and 1-10 parts by weight of licorice.
2. In paragraph 1, The above-mentioned neurogenic pulmonary edema is a pulmonary edema caused by cranial injury or central nervous system disease, and is a Chinese medicine composition.
3. In paragraph 1, A Chinese medicine composition in which the above-mentioned neurogenic pulmonary edema is one or more selected from cranial trauma, surgery, subarachnoid hemorrhage, cerebral embolism, cerebral hemorrhage, brainstem ossification, intracranial tumor, acute cerebral edema, epilepsy, and pulmonary edema resulting from complications of central nervous system lesions after viral infection.
4. In paragraph 1, The above Chinese medicine composition is a Chinese medicine composition manufactured from the following raw materials in parts by weight: 15 parts by weight of *Hyeonggae*, 15 parts by weight of *Bangpung*, 15 parts by weight of *Ganghwal*, 15 parts by weight of Aralia continentalis, 15 parts by weight of Bupleurum chinense, 15 parts by weight of Angelica dahurica, 15 parts by weight of Cnidium officinale, 15 parts by weight of Angelica dahurica, 15 parts by weight of Poria cocos, 15 parts by weight of balloon flower root, and 5 parts by weight of licorice.
5. In any one of paragraphs 1 through 4, The above Chinese medicine composition is a Chinese medicine composition prepared as a tablet, capsule, pill, granule, or drink by adding one or more pharmaceutically acceptable medicinal adjuvants.
6. In paragraph 5, The above Chinese medicine composition is a Chinese medicine composition prepared as a granule by adding one or more pharmaceutically acceptable medicinal adjuvants.
7. delete
8. delete
9. delete

Description

Use of a type of Chinese medicine composition in the manufacture of drugs for the treatment of neurogenic pulmonary edema The present invention belongs to the field of pharmaceutical technology and relates to a new use of a type of Chinese medicinal composition, and more specifically, to the use of a type of Chinese medicinal composition in the manufacture of a drug for treating neurogenic pulmonary edema. The Chinese medicinal composition comprises *Schizonepeta tenuifolia*, *Saposhnikovia divaricata*, *Angelica dahurica*, *Aralia continentalis*, *Bupleurum chinense*, *Peony pea*, *Cnidium officinale*, *Prunus persica*, *Prunus mume*, *Paprika mahogany*, and *Glycyrrhiza uralensis*. Pulmonary edema occurs when fluid accumulates in the interstitial space or within the alveoli, leading to an increase in the volume of extravascular fluid or elevated intracapillary pressure. Major clinical symptoms of acute pulmonary edema include dyspnea, cyanosis, cough, colorless or pinkish foamy sputum, and diffuse wet murmurs in the lungs; in severe cases, it can lead to respiratory failure and even death. Pulmonary edema has a high incidence rate and a poor prognosis, and it is considered a common and serious condition in clinical practice. Pulmonary edema can be divided into cardiogenic and non-cardiogenic pulmonary edema. Among these, cardiogenic pulmonary edema occurs when a large amount of blood accumulates in the pulmonary circulation due to heart disease, which causes a rapid increase in the blood volume returning to the heart and the right ventricular ejection volume, or a sudden and severe decrease in the left ventricular ejection volume. This leads to a rapid rise in pulmonary capillary venous pressure. When the colloid osmotic pressure within the pulmonary capillaries rises excessively, changes in the hemodynamics of the capillaries occur, causing blood stasis in the pulmonary circulation. Additionally, the increased permeability of the pulmonary capillary walls causes fluid to leak through the walls, resulting in pulmonary edema. Although there are relatively many causes of non-cardiac pulmonary edema, the pathogenesis mechanisms mainly include elevated alveolar capillary blood pressure, increased alveolar capillary permeability, decreased plasma colloid osmolality, or other factors such as lymphatic obstruction and increased interstitial negative pressure. Neurogenic pulmonary edema refers to a clinical syndrome of acute pulmonary edema caused by acute interstitial and alveolar fluid exudation resulting from cranial injury or central nervous system disease in the absence of primary heart or lung disease. Clinically, pulmonary edema is treated using antibiotics, corticosteroids, diuretics, and vasodilators depending on the various factors causing it; however, all of these drugs have some degree of side effects. For example, vasodilators can cause hypotension, and diuretics can lead to electrolyte imbalances. The disease name "pulmonary edema" does not exist in classical medical literature, and although the name is not recorded in ancient Chinese medical texts, symptoms similar to pulmonary edema are referred to in Chinese medicine as "Zhiyin ( )", "short gas", "short gas" )", "Handwriting( )", "The above seawater( It is identical to )". Based on the major clinical symptoms of pulmonary edema, combining ancient understanding with modern clinical practice, the etiology of pulmonary edema is external pathogenic dampness in the lungs ( ), heart disease, lung disease, and chronic physical weakness ( It can be reduced to three aspects. Hyungbang granules are formulated by combining Schizonepeta tenuifolia, Saposhnikovia divaricata, Angelica dahurica, Aralia continentalis, Bupleurum chinense, Peucedanum citrus, Ligusticum chuanxiong, Citrus aurantium, Poria cocos, Platycodon grandiflorus, and Glycyrrhiza glabra, and are diaphoretic and antipyretic ( It has the action of dispelling wind and expelling phlegm ( ), Cheongpyejihae( It can do ) and external wind-cold ( It is known to have very good effects on a series of symptoms caused by ) and is safe with few side effects. The present invention provides a novel Chinese medicinal composition used for the treatment of a type of neurogenic pulmonary edema, said Chinese medicinal composition comprising *Schizonepeta tenuifolia*, *Saposhnikovia divaricata*, *Angelica dahurica*, *Aralia continentalis*, *Bupleurum chinense*, *Peony pea*, *Cnidium officinale*, *Prunus mume*, *Poria cocos*, *Platycodon grandiflorus*, and *Glycyrrhiza uralensis*. The present invention is a continuation of the development of the use of the existing product, *Hyungbang Granules*, and based on clinical feedback, the inventor has conducted research and development on new uses for *Hyungbang Granules* and its prescriptions. According to experimental studies, *Hyungbang Granules* can significantly reduce lung fluid and lung wetness/dryness in rats with oleic acid-induced neurogenic pulmonary edema, imp